| Assessment Status | Assessment process complete |
| HTA ID | 20015 |
| Drug | House Dust Mite Extract |
| Brand | Acarizax ® |
| Indication | For the treatment of adult patients (18-65 years) diagnosed by clinical history and a positive test of HDM sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication. |
| Assessment Process | |
| Rapid review commissioned | 12/03/2020 |
| Rapid review completed | 30/04/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM extract compared with the current standard of care. |
The company has not submitted a HTA dossier to the NCPE; therefore the cost-effectiveness of the technology could not be proven.
